LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

NCT07370597 · clinicaltrials.gov ↗
RECRUITING
Status
110
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Jules Bordet Institute